SCHEMBL6129642

SCHEMBL6129642

NC(=O)c1cccc2c1c1c(OC(=O)CO)cc(-c3ccccc3)cc1n2Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 19/20 0.41
PLA2G1B P04054 5/20 0.40
PLA2G10 O15496 4/20 0.39
PLA2G2E Q9NZK7 4/20 0.39
PLA2G5 P39877 3/20 0.39
PLA2G2F Q9BZM2 3/20 0.39
PLA2G2D Q9UNK4 3/20 0.39
PLA2G6 O60733 1/20 0.38
PLA2G2C Q5R387 1/20 0.38
PLA2G12B Q9BX93 1/20 0.38
PLA2G12A Q9BZM1 1/20 0.38
PLA2G3 Q9NZ20 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6129601 0.94 PLA2G2A (0.39) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL27845212 0.89 PLA2G2A (0.44) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL8575181 0.88 PLA2G2A (0.46) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL6612768 0.88 PPARG (0.38) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL6534781 0.88 HSD17B10 (0.37) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL27576590 0.88 PLA2G2A (0.41) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL6129602 0.86 PLA2G2A (0.41) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL6129648 0.86 PLA2G2A (0.46) PLA2G2APLA2G10
SCHEMBL29862573 0.85 PLA2G2A (0.54) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5
SCHEMBL818840 0.85 PLA2G2A (0.54) PLA2G2APLA2G1BPLA2G10PLA2G2EPLA2G5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1043991-A4 TREATMENT FOR ALZHEIMER'S DISEASE LILLY CO ELI (US) 2005-02-02 EP claimed
JP-2004503586-A 2004-02-05 JP claimed
EP-1303262-A2 USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS ELI LILLY AND COMPANY (US) 2003-04-23 EP claimed
EP-1259260-A1 COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES ELI LILLY AND COMPANY (US) 2002-11-27 EP claimed
WO-2002005796-A2 USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS ELI LILLY AND COMPANY (US) 2002-01-24 WO claimed
JP-2001522884-A 2001-11-20 JP claimed
WO-2001049323-A1 COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES ELI LILLY AND COMPANY (US) 2001-07-12 WO claimed
EP-1043991-A1 TREATMENT FOR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 2000-10-18 EP claimed
WO-1999025340-A1 TREATMENT FOR ALZHEIMER'S DISEASE ELI LILLY AND COMPANY (US) 1999-05-27 WO claimed
EP-1011670-A4 METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS LILLY CO ELI (US) 2004-10-27 EP disclosed
EP-1259260-A1 COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES ELI LILLY AND COMPANY (US) 2002-11-27 EP disclosed
WO-2001049323-A1 COMBINATION THERAPY FOR THE TREATMENT OF INFLAMMATORY AND RESPIRATORY DISEASES ELI LILLY AND COMPANY (US) 2001-07-12 WO disclosed
EP-1011670-A1 METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS ELI LILLY AND COMPANY (US) 2000-06-28 EP disclosed
WO-1999009978-A1 METHOD FOR TREATMENT OF NON-RHEUMATOID ATHRITIS ELI LILLY AND COMPANY (US) 1999-03-04 WO disclosed